Context: Hypothyroidism in pregnancy can lead to adverse maternal and fetal outcomes. Although screening of high-risk women is advocated, universal screening remains controversial.
cially in women with elevated serum anti-thyroid antibody titers (6 -10) . Women with thyroid autoimmunity are also at an increased risk for postpartum thyroiditis (PPT) (11, 12) and for developing overt hypothyroidism in the future (13) . In addition, maternal hypothyroidism may have adverse consequences on fetal neurodevelopment and lead to decreased child intelligence quotient (IQ) (14, 15) .
Professional societies have endorsed universal screening of pregnant women (16, 17) or selective screening of women at high risk for thyroid dysfunction (18 -20) , even though the latter approach may miss 30 -50% of the hypothyroid cases (21, 22) .
Screening of the general population for thyroid disease has been found to be cost-effective in adults older than 35 yr (23) and 60 yr old (24) . Two prior analyses have also demonstrated the cost-effectiveness of universal screening of pregnant women for thyroid disease compared with no screening (25, 26) , but these studies were limited by the absence of randomized controlled trial (RCT) data showing levothyroxine benefit. Recently two RCTs have shown that levothyroxine therapy, when compared with placebo, demonstrates significant improvement in obstetrical outcomes in pregnant women with autoimmune thyroid disease (AITD) (6, 7) .
The objective of the current study was to compare the cost-effectiveness of three screening strategies of pregnant women for AITD in the first trimester, using TSH and antithyroid peroxidase (TPO) antibodies: 1) universal screening, 2) screening of only women at high risk for AITD, and 3) no screening.
Materials and Methods

Decision model
A decision model was developed using TreeAge Pro 2009 Suite (Williamstown, MA) to investigate the difference in costs and health benefits among three alternatives of screening pregnant women for AITD. The three screening strategies include the following: 1) universal screening, 2) risk-based screening, and 3) no screening (Fig. 1A) . Universal screening of all pregnant women is contrasted with risk-based screening of only those pregnant women at high risk for AITD, as defined in The Endocrine Society's clinical practice guidelines on management of thyroid disease in pregnancy (19) . Only women with no known history of thyroid disease were included in the model. Screening occurred once in the woman's lifetime, at the age of 25 yr (mean age of mothers in their first pregnancy in the United States) (27) , during the first trimester of pregnancy. A societal perspective, considering costs rather than charges for care regardless of the payer and discounted future costs and utilities at 3% per year, was employed (28) . Lifetime medical costs and utilities related to the treatment of AITD and sequelae were included but not other medical costs or nonmedical costs.
Screening used serum TSH and anti-TPO antibody levels; these were added to the laboratory tests obtained at the first prenatal visit (6 -12 wk of gestation). The subjects who screened positive underwent further testing, follow-up, and treatment. Women with AITD were at risk for miscarriage, preterm delivery, PPT, and future development of overt hypothyroidism. Treatment of women with AITD was considered to be beneficial only in those adverse outcomes that have been shown to improve with treatment in RCTs. Therefore, other potential benefits, such as improvement in child IQ, were not included in the base-case analysis, given the absence of RCT data. Subsequently all women entered a Markov cycle in which they underwent annual transitions between the five health states depicted in Fig. 1B .
Testing and treatment strategies
In screened patients, TSH and anti-TPO antibody levels were measured and serum was saved for further testing. If TSH was high (Ͼ5 mIU/liter), regardless of anti-TPO antibody status, serum was then tested for total T 4 levels (TT4). Based on the results, a diagnosis of subclinical (normal TT4 for pregnancy appropriate range) or overt (low TT4) hypothyroidism was reached and the patient was referred to an endocrinologist. Table 1 outlines the testing and treatment strategies planned for screened women with overt hypothyroidism, subclinical hypothyroidism, and other possible first-trimester results. Throughout the model, women could be compliant or not with levothyroxine treatment. Noncompliant women remained untreated until they became compliant (median of 2.5 yr).
Probabilities
We derived the probabilities for the decision tree and the Markov state transitions from prevalence studies and RCTs in peer-reviewed journals, after extensive review of the literature (Table 2) . We varied the prevalence of the anti-TPO antibodies as a function of maternal age. When the probabilities were not available, we estimated them using clinical judgment. We estimated compliance with levothyroxine to be 80 and 90% in nonpregnant and pregnant women, respectively. Based on clinical experience, we estimated the median time to diagnosis of unscreened pregnant women with overt hypothyroidism or symptomatic subclinical hypothyroidism to be 2.5 yr. This time was more conservative than 5 yr, the reported median time to diagnosis of hypothyroidism in unscreened women with elevated TSH in pregnancy in a previous study (14) . We varied all parameter values extensively in sensitivity analyses.
Costs
The costs for laboratory tests were obtained from the 2009 Medicare Clinical Laboratory Fee Schedule (29). The costs for clinic visits were obtained from the 2009 Medicare payment amounts for services provided in a facility (30) ( Table 2 ). The cost of levothyroxine treatment was obtained from the 2009 Redbook (mean of generics, Levoxyl, and Synthroid) (31) . Screening cost consisted of an anti-TPO antibody titer [Current Procedural Terminology (CPT) 86 376] and TSH test (CPT 84 443). Follow-up testing after screening, in women with TSH greater than 5, was that of a TT4 (CPT 84 436). The cost of the initial visit to the endocrinologist was assumed to be that of a 40-min outpatient consultation (CPT 99 243). Hypothyroidism treatment costs were calculated for the different scenarios described above using the costs of a 15-min follow-up outpatient visit (CPT 99 213), TSH test, TT4 test during pregnancy or free T4 (CPT 84 439) in nonpregnant women, and annual cost of levothyroxine treatment. The cost of the workup of unscreened women with hypothyroidism and PPT costs were obtained from prior studies (23, 37) . All costs were adjusted to 2009 U.S. dollars using the gross domestic product deflator inflation calculator (http://cost.jsc.nasa.gov/inflateGDP.html). In the Markov model, we included only lifetime costs associated with the diagnosis and treatment of overt hypothyroidism; we did not include medical costs due to other conditions.
Patient preferences
Utilities, ranging from 0 to 1, were used to describe patient preferences for the different health states (Table 2) . A utility of 0 was assigned to the dead state and 1 to the ideal health state. We obtained utilities for overt hypothyroidism, PPT, spontaneous miscarriage, and preterm delivery from the literature (33, 37-41). We assigned a utility of 1 to asymptomatic subclinical hypothyroidism and asymptomatic PPT. We estimated symp- tomatic untreated subclinical hypothyroidism to have a utility of 0.9, which increased to 1 if treated. For use in our sensitivity analysis, to derive the utility of having a child with an IQ of 85 or less, we surveyed five pediatricians and we averaged the values given. We assigned a lifetime utility decrement only to the mother of the child with low IQ.
Assumptions of the model
The following additional assumptions were made:
1. Hyperthyroidism was excluded from the model. Overt hyperthyroidism is usually diagnosed through symptoms, whereas subclinical hyperthyroidism, which is much more common, has no adverse consequence in pregnancy (53). 2. TT4 (normal range 1.5 ϫ the nonpregnant reference range) was used as a surrogate estimate of free T 4 during pregnancy. 3. Overtly hypothyroid women are all symptomatic and once diagnosed need lifelong therapy and follow-up. 4. Women diagnosed with subclinical hypothyroidism at screening are not treated after the first postpartum year. 5. Asymptomatic unscreened pregnant women with subclinical hypothyroidism remain undiagnosed. Women with symptomatic subclinical hypothyroidism have a 25% probability of diagnosis by 12 months postpartum. Women who develop symptomatic subclinical hypothyroidism later remain undiagnosed until they develop overt hypothyroidism. 6. All compliant patients are assumed to undergo adequate treatment and normalize their TSH. 7. Postpartum thyroiditis is correctly diagnosed in all symptomatic patients in the screened, anti-TPO antibody-positive group. All other symptomatic postpartum women have a 25% probability of diagnosis, whereas 75% incur additional cost of workup of their symptoms (37).
8. Women are assumed to not die until after the first postpartum year. 9. In the base-case analysis, we assume that screened women who are anti-TPO antibody positive with TSH less than 2.5 who then develop high TSH in the subsequent trimesters do not have increased risk of adverse obstetrical outcomes because there are yet no epidemiological data on this issue. Despite this, we assume that these women are treated and incur costs of testing and treatment without benefit. This results in underestimation of cost-effectiveness of screening by the current model.
Results
Base-case analysis
Under base-case assumptions, risk-based screening increased quality-adjusted life expectancy by 3.69 d at a cost of $68 relative to no screening for an incremental costeffectiveness ratio (ICER) of $6,753 per quality-adjusted life-year (QALY). Universal screening increased qualityadjusted life expectancy by 9.97 d at a cost of $198 relative to the risk-based screening for an ICER of $7,258 per QALY (Table 3) . Universal screening compared with no screening gave an ICER of $7,138 per QALY. The results were similar when we used the product of utilities rather than the minimum utility in scenarios requiring combinations of disutilities, such as the combination of a mother with untreated hypothyroidism who has a miscarriage (data not shown). Clinical strategies by first-trimester screening results, indicating planned thyroid function testing and levothyroxine treatment during and after pregnancy. Screened women that require levothyroxine treatment are followed, after the initial screening tests and endocrine consultation, with follow-up clinic visits and thyroid function tests once per trimester during pregnancy and one to three times in the postpartum year, depending on their diagnosis. In noncompliant women, planned treatment does not occur. FT4, Free T4; Ab, antibody; OH, overt hypothyroidism; SH, subclinical hypothyroidism. 
Sensitivity analyses
The results were robust to one-way sensitivity analysis in all parameters (Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org). In terms of costs, the analysis was most sensitive to the cost of TSH, but universal screening remained highly cost-effective compared with no screening, even at a TSH cost of $50. When screening and diagnostic costs (TSH, anti-TPO antibody level, and TT4) were doubled, risk-based screening was cost-effective at The analysis was also robust across a wide range of utilities and probabilities tested. Similar to our previous study (25) , the analysis was most sensitive to the annual probability of diagnosing overt hypothyroidism in women who are unscreened or those who have negative screening tests; ICERs, however, remained below $23,000/QALY, even when we assumed that 80% of unscreened women would be diagnosed annually.
Cost-effectiveness of different clinical scenarios
The base model used conservative estimates both for probabilities of adverse outcomes and for benefits of levothyroxine treatment. When no data were available from RCTs, no benefit of treatment was assumed. In sensitivity analysis, by varying selective variables in a clinically meaningful direction, the cost-effectiveness of screening was explored in a variety of hypothetical clinical scenarios in which additional benefit of screening was assumed either for an obstetrical outcome or for child IQ. Additionally, we explored a scenario in which the benefits of screening and treatment were more limited than in the base-case scenario and did not apply to women with subclinical hypothyroidism.
Obstetrical outcome scenarios
We explored four scenarios that assumed benefits of levothyroxine treatment on obstetrical outcomes for additional groups of women.
• Scenario 1 assumed that women who are anti-TPO antibody positive with TSH less than 2.5 in the first trimester that go on to have a TSH greater than 5 later in pregnancy are at increased risk for preterm delivery (16.3%) and that treatment decreases this risk (to 4.8%).
• Scenario 2 assumed that the miscarriage rate in anti-TPO antibody-negative women with TSH 2.5-5 decreases from 6.1 to 3.6% with treatment.
• Scenario 3 assumed that anti-TPO antibody-negative women with TSH greater than 5 have decreased risks of preterm delivery (from 7.0 to 5.6%) and decreased risk of miscarriage (from 7.6 to 3.6%) with treatment.
• Scenario 4 assumed that women who are anti-TPO antibody positive with TSH less than 2.5 in the first trimester are treated during pregnancy and that treatment decreases their miscarriage rate from 6.1 to 3.6%.
In all of the above scenarios of obstetrical outcomes, both risk-based and universal screening remained highly cost-effective (Table 4) . In a best case obstetrical scenario (scenario 5), which included all of the above additional obstetrical benefits, screening again remained cost-effective with an ICER of $9,968 per QALY for high-risk screening compared with no screening and an ICER of $11,369 per QALY for universal screening compared with high-risk screening ( Table 4 ). Scenarios that reduce miscarriage generally increase the ICER, as delivery costs are higher than miscarriage costs, but screening strategies remain cost-effective.
Scenario assuming effect on child IQ in untreated patients
In this scenario, a detrimental effect of untreated subclinical hypothyroidism and overt hypothyroidism on child IQ and amelioration with levothyroxine treatment was assumed (additional assumptions are listed in Table  2 ). Both risk-based screening and universal screening were cost-saving, with higher quality-adjusted life expectancies at a lower cost than no screening (Table 4) . Universal screening was most cost-saving, providing an additional 14.1 quality-adjusted days and saving $1,533 compared with no screening (data not shown). This finding was robust across further sensitivity analyses, which varied IQrelated assumptions across clinically meaningful ranges. Additionally, in a scenario in which we assumed all obstetrical benefits and a child IQ benefit, both universal screening and risk-based screening were cost-saving (data not shown). When we assumed that only untreated maternal overt hypothyroidism had a detrimental effect on child IQ, universal screening was cost-saving compared with riskbased screening at a mean IQ point loss of 5 or higher.
Benefit assigned only to women with overt hypothyroidism
In a hypothetical scenario in which subclinical hypothyroidism has no adverse outcomes and does not get treated, and the only benefits of screening consist of detection and treatment of overt hypothyroidism and closer follow-up of detected anti-TPO antibody positive women, with more prompt diagnosis of PPT and overt hypothyroidism when they develop, our results were substantially similar to the base case (Table 4) .
Discussion
AITD and hypothyroidism are prevalent among reproductive-age women (1) and, untreated, can cause adverse obstetrical outcomes such as miscarriage and preterm delivery (8 -10) . Women with AITD are also at increased risk of PPT (11, 12) and development of hypothyroidism in the future (13) . Retrospective data also suggest that untreated maternal hypothyroidism adversely affects fetal intellectual development (14, 15, 54, 55) . Recent RCT have established the benefit of levothyroxine treatment in decreasing rates of obstetrical adverse outcomes (6, 7) . Currently The Endocrine Society recommends only screening of high-risk women (19) ; nevertheless, such practice may miss 30 -50% of women with AITD that would benefit from treatment (21, 22) .
Two previous cost-effectiveness analyses have shown that universal screening of pregnant women for AITD is cost-effective compared with no screening (25, 26) . The current study is the first to show that universal screening of pregnant women for AITD is also highly cost-effective compared with high-risk screening only, with an ICER of $7,258 per QALY, well below the accepted threshold for cost-effectiveness of $50,000 per QALY. The analysis was robust to variation of all parameters and across different hypothetical clinical scenarios tested. When we assumed no benefits of detection and treatment of subclinical hypothyroidism, universal screening remained highly cost-effective compared with risk-based screening at $7,335 per QALY. Both universal screening and risk-based screening became cost-saving when we assumed that untreated maternal hypothyroidism results in decreased child IQ.
The current study has important strengths. Unlike prior studies in this field, we used only data from RCTs regarding rates of adverse obstetrical outcomes. Whenever there were no data from RCTs available, we chose the most conservative assumptions for our base-case model, which underestimates the potential economic benefit of screening.
Limitations of the present study include that probabilities were estimated when data were lacking. We minimized the effect of the introduced uncertainty by making the most conservative assumptions. The data on child IQ were not included in our base-case analysis due to the lack of published RCT data on this topic. This, again, resulted in underestimation of the potential benefit of screening. Finally, the results apply to women who have access to prenatal care, including opportunities for first-trimester thyroid screening.
One should also note certain characteristics of the current study when assessing its applicability to different populations. The two RCTs that we used as sources for the effects of levothyroxine treatment on adverse obstetrical outcomes were both performed in southern Italy, an area of mild iodine deficiency, in which the initial obstetrical visit occurred at 9 -10 wk. One needs to be careful before extrapolating results to countries with different levels of iodine nutrition or in women who are screened at later gestational ages. In addition, to calculate our costs, we used Medicare payment amounts and cost of levothyroxine in the United States. Therefore, our results may not be applicable to other countries with different medical costs.
Data from RCTs such as the ongoing Thyroid Antibodies and Levothyroxine study (56) , which assesses the efficacy of levothyroxine in improving live births in patients with AITD, will be useful to incorporate in future economic analyses. The results of the Controlled Antenatal Thyroid Screening study in Europe and a National Institute of Health-sponsored study in the United States (57, 58) , both current RCTs investigating the effects of levothyroxine treatment in pregnancy on child IQ, will also be of interest, although both of these studies are limited by the fact that levothyroxine intervention was allowed to start well into the second trimester, which may be past the point of reversible effects on neurodevelopment.
In conclusion, both universal screening and risk-based screening of pregnant women in the first trimester for AITD are highly cost-effective strategies compared with no screening. Universal screening is also highly cost-effective compared with screening of only high-risk women.
Even in a scenario that assumed no benefit of treating subclinical hypothyroidism, universal screening remained cost-effective. The medical community should seriously consider screening all pregnant women for AITD.
